From Landmark Trials to Evidence-Based Therapy for Resistant, Refractory, High Risk and/or Challenging Patients with MAC Lung Infection

From Landmark Trials to Evidence-Based Therapy for Resistant, Refractory, High Risk and/or Challenging Patients with MAC Lung Infection

Continue to Test Back to Symposium

The Role, Safety, Indications, Evidence, and Efficacy of Novel, Inhaled Antimicrobial Formulations

Published

August 27, 2021

Created by

CMEducation Resources symposium

Related Presenters

Rachel Thomson, MD

Rachel Thomson, MD

Director, Mycobacterial Diseases
Gallipoli Medical Research Institute
University of Queensland
Brisbane, QLD, Australia